ASX - Delayed Quote AUD

Resonance Health Limited (RHT.AX)

0.0850 0.0000 (0.00%)
At close: April 26 at 10:06 AM GMT+10

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.
NameTitlePayExercisedYear Born
Mr. Mitchell M. Wells B.Com., B.Comm, L.L.B., LLB Company Secretary & Non Executive Director 274.56k -- 1975
Mr. Andrew Duncan Harrison BCom (Hons), MAICD Chief Executive Officer -- -- 1971
Mr. Benjamin Carruthers Chief Financial Officer -- -- --
Ms. Liesl Ellies General Counsel -- -- --
Mr. Chad Tondut Communications Manager and GM of Products & Portfolio -- -- --
Mr. Ajay Nair General Manager of Global Sales & Marketing -- -- --
Dr. Timothy Guy St. Pierre B.Sc(Hons), Ph.D. Chief Research Scientist 206.94k -- --
Dr. Wenjie Pang Ph.D. Chief Scientific Officer – Imaging & AI -- -- --
Dr. Sherif Boulos Ph.D. Chief Scientific Officer of Molecular -- -- --

Resonance Health Limited

141 Burswood Road
Level 1
Burswood, WA 6100
Australia
61 8 9286 5300 https://www.resonancehealth.com
Sector: 
Healthcare

Description

Resonance Health Limited, a healthcare technology and services company, designs, develops, manufactures, and commercializes software-as-medical devices in the Asia Pacific, North America, Europe, the Middle East, and Africa. The company offers FerriScan, a non-invasive MRI based system for quantifying liver iron concentration (LIC); FerriSmart, an artificial intelligence (AI) assisted device for the automated real-time assessment of LIC; HepaFat-AI, an AI-trained device for the automated real-time multi-metric measurement of liver-fat; CardiacT2, a dual analysis service with FerriScan for assessing heart iron loading; HepaFat-Scan, a non-invasive MRI-based solution for the assessment of liver-fat in liver tissue; and LiverSmart, a non-invasive MRI-based multi-parametric device combining FerriSmart and HepaFat-AI into a consolidated report. It also provides quantitative imaging measurements and CRO services, such as quality-assured image analysis, project and data management, and issue resolution services; biomarkers, genomics, and laboratory analysis services, as well as works with third party pathology laboratories for blood/sample collection and for standard biochemical/lab safety assessments; design and protocol development, and project management and monitoring services; assessment of subject inclusion or exclusion, evaluating the safety profile of a new therapy, and supporting primary and secondary end-points demonstrating drug efficacy services; and phantoms for the MRI machines. The company serves clinicians for the management of human diseases; and pharmaceutical and therapeutic companies for their clinical trials. Resonance Health Limited was incorporated in 1987 and is headquartered in Burswood, Australia.

Corporate Governance

Resonance Health Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Jul 23, 2024 - Jul 29, 2024
Resonance Health Limited Earnings Call

Related Tickers